Literature DB >> 28189178

Syndromes of Thrombotic Microangiopathy.

Joseph J Shatzel1, Jason A Taylor2.   

Abstract

Thrombotic thrombocytopenia purpura (TTP) and the hemolytic uremic syndrome (HUS) are rare thrombotic microangiopathies that can be rapidly fatal. Although the acquired versions of TTP and HUS are generally highest on this broad differential, multiple rarer entities can produce a clinical picture similar to TTP/HUS, including microangiopathic hemolysis, renal failure, and neurologic compromise. More recent analysis has discovered a host of genetic factors that can produce microangiopathic hemolytic syndromes. This article discusses the current understanding of thrombotic microangiopathy and outlines the pathophysiology and causative agents associated with each distinct syndrome as well as the most accepted treatments. Published by Elsevier Inc.

Entities:  

Keywords:  Atypical hemolytic uremic syndrome (aHUS); Hemolytic uremic syndrome (HUS); Microangiopathic hemolytic anemia (MAHA); Pregnancy induced microangiopathic hemolytic anemia; Thrombotic thrombocytopenic purpura (TTP); Transplant induced microangiopathic hemolytic anemia

Mesh:

Substances:

Year:  2016        PMID: 28189178     DOI: 10.1016/j.mcna.2016.09.010

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  19 in total

1.  Biopsy-proven thrombotic microangiopathy without schistocytosis on peripheral blood smear: A cautionary tale.

Authors:  Catherine R Murphree; Nga N Nguyen; Joseph J Shatzel; Sven R Olson; Paul D Chung; Joseph B Lockridge; Nicole K Andeen; Thomas G DeLoughery
Journal:  Am J Hematol       Date:  2019-06-17       Impact factor: 10.047

2.  Insights into pregnancy associated and atypical hemolytic uremic syndrome.

Authors:  Sophie Grand'Maison; Stephen Lapinsky
Journal:  Obstet Med       Date:  2018-07-12

3.  The Differential Diagnosis and Treatment of Thrombotic Microangiopathies.

Authors:  Martin Bommer; Manuela Wölfle-Guter; Stephan Bohl; Florian Kuchenbauer
Journal:  Dtsch Arztebl Int       Date:  2018-05-11       Impact factor: 5.594

4.  Microangiopathy associated with gemcitabine: a drug interaction with nab-paclitaxel? A case series and literature review.

Authors:  Jeanne Allard; Mathilde Bonnet; Lucie Laurent; Mohamed Bouattour; Marie-Pauline Gagaille; Vincent Leclerc
Journal:  Eur J Clin Pharmacol       Date:  2022-05-04       Impact factor: 2.953

5.  Intracellular origin and ultrastructure of platelet-derived microparticles.

Authors:  A A Ponomareva; T A Nevzorova; E R Mordakhanova; I A Andrianova; L Rauova; R I Litvinov; J W Weisel
Journal:  J Thromb Haemost       Date:  2017-07-15       Impact factor: 5.824

6.  Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura.

Authors:  X Long Zheng; Sara K Vesely; Spero R Cataland; Paul Coppo; Brian Geldziler; Alfonso Iorio; Masanori Matsumoto; Reem A Mustafa; Menaka Pai; Gail Rock; Lene Russell; Rawan Tarawneh; Julie Valdes; Flora Peyvandi
Journal:  J Thromb Haemost       Date:  2020-09-11       Impact factor: 5.824

7.  A case of acute pancreatitis-induced microangiopathic hemolytic anemia with thrombocytopenia.

Authors:  Kevin M Hill; Danielle Moorman; Jonathan Mack; Carol Gonsalves; Roy Khalife
Journal:  J Thromb Thrombolysis       Date:  2020-01       Impact factor: 2.300

8.  Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura.

Authors:  Elie Azoulay; Philippe R Bauer; Eric Mariotte; Lene Russell; Paul Knoebl; Ignacio Martin-Loeches; Frédéric Pène; Kathryn Puxty; Pedro Povoa; Andreas Barratt-Due; Jose Garnacho-Montero; Julia Wendon; Laveena Munshi; Dominique Benoit; Michael von Bergwelt-Baildon; Marco Maggiorini; Paul Coppo; Spero Cataland; Agnès Veyradier; Andry Van de Louw
Journal:  Intensive Care Med       Date:  2019-10-07       Impact factor: 17.440

9.  Clinical characteristics, triggering etiologies, and response of plasmapheresis in thrombotic microangiopathy in Taiwan.

Authors:  Ching-Hu Chung; I-Jung Tsai; Min-Hua Tseng; Hsin-Hsu Chou; You-Lin Tain; Jeng-Daw Tsai; Yuan-Yow Chiou; Yee-Hsuan Chiou; Ching-Yuang Lin
Journal:  Medicine (Baltimore)       Date:  2021-05-21       Impact factor: 1.817

10.  Caplacizumab Model-Based Dosing Recommendations in Pediatric Patients With Acquired Thrombotic Thrombocytopenic Purpura.

Authors:  Martin Bergstrand; Emma Hansson; Bernard Delaey; Filip Callewaert; Rui De Passos Sousa; Maria Laura Sargentini-Maier
Journal:  J Clin Pharmacol       Date:  2021-11-29       Impact factor: 2.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.